Monthly shot may boost opioid treatment success in hospitals
NCT ID NCT04345718
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a once-monthly injection of extended-release buprenorphine helps hospitalized patients with moderate to severe opioid use disorder stay in treatment better than usual care (like daily pills or methadone). Over 300 adults were randomly assigned to receive either the injection or standard medication before leaving the hospital. Researchers tracked how many were still engaged in treatment 34 days later, with follow-ups at 90 and 180 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
extended-release buprenorphine
What this could lead to
If successful, this could show that a monthly injection of buprenorphine helps more people stay in treatment for opioid use disorder compared to daily pills or other standard options.
What could go wrong
This is a completed Phase 2/3 trial, but results may not apply to all patients or settings. Extended-release buprenorphine can have side effects like injection site reactions or withdrawal symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBSTANCE USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston University
Boston, Massachusetts, 02118, United States
-
Hennepin Healthcare Research Institute
Minneapolis, Minnesota, 55404, United States
-
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States